Your browser doesn't support javascript.
loading
The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.
Witkin, J M; Cerne, R; Davis, P G; Freeman, K B; do Carmo, J M; Rowlett, J K; Methuku, K R; Okun, A; Gleason, S D; Li, X; Krambis, M J; Poe, M; Li, G; Schkeryantz, J M; Jahan, R; Yang, L; Guo, W; Golani, L K; Anderson, W H; Catlow, J T; Jones, T M; Porreca, F; Smith, J L; Knopp, K L; Cook, J M.
Afiliação
  • Witkin JM; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Laboratory of Antiepileptic Drug Discovery, Department of Neurological Surgery, Indiana University School of Medicine, Indianapoli
  • Cerne R; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Davis PG; Millsaps College, Jackson, MS, USA.
  • Freeman KB; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
  • do Carmo JM; Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.
  • Rowlett JK; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
  • Methuku KR; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Okun A; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Gleason SD; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Li X; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Krambis MJ; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Poe M; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Li G; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Schkeryantz JM; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Jahan R; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Yang L; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Guo W; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Golani LK; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Anderson WH; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Catlow JT; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Jones TM; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Porreca F; Department of Pharmacology, University of Arizona, Tucson, AZ, USA.
  • Smith JL; Laboratory of Antiepileptic Drug Discovery, Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Knopp KL; The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
  • Cook JM; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Pharmacol Biochem Behav ; 180: 22-31, 2019 05.
Article em En | MEDLINE | ID: mdl-30825491

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazóis / Nervos Espinhais / Medição da Dor / Receptores de GABA-A / Sinergismo Farmacológico / Formaldeído / Analgésicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: Pharmacol Biochem Behav Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazóis / Nervos Espinhais / Medição da Dor / Receptores de GABA-A / Sinergismo Farmacológico / Formaldeído / Analgésicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: Pharmacol Biochem Behav Ano de publicação: 2019 Tipo de documento: Article